The first GLP-1 drug, Exenatide (brand name Byetta), was approved by the Food and Drug Administration in 2005 to treat type 2 diabetes
12 Therapeutic GLP-1 receptor agonism has been associated with delayed gastric emptying, which aids in weight loss by reducing appetite, increasing satiety, and reducing energy intake
That's when the magic really happens, as it completely bypasses your digestive system where oral supplements typically break down
Lets work together to optimize your energy, hormones, and digestion, starting from the inside out
This variability is influenced by differences in the permeability of the bloodbrain barrier (BBB) and the bloodcerebrospinal fluid (CSF) barrier, as well as by region-specific expression of enzymes involved in glutathione metabolism